189 related articles for article (PubMed ID: 23370512)
41. The role of molecular imaging in modern drug development.
Cunha L; Szigeti K; Mathé D; Metello LF
Drug Discov Today; 2014 Jul; 19(7):936-48. PubMed ID: 24434047
[TBL] [Abstract][Full Text] [Related]
42. Iodine-124 as a label for pharmacological PET imaging.
Belov VV; Bonab AA; Fischman AJ; Heartlein M; Calias P; Papisov MI
Mol Pharm; 2011 Jun; 8(3):736-47. PubMed ID: 21361362
[TBL] [Abstract][Full Text] [Related]
43. Translating a radiolabeled imaging agent to the clinic.
Griffiths GL; Vasquez C; Escorcia F; Clanton J; Lindenberg L; Mena E; Choyke PL
Adv Drug Deliv Rev; 2022 Feb; 181():114086. PubMed ID: 34942275
[TBL] [Abstract][Full Text] [Related]
44. [Development of Radiolabeled Molecular Imaging Probes for in Vivo Analysis of Biological Function].
Ueda M
Yakugaku Zasshi; 2016; 136(4):659-68. PubMed ID: 27040347
[TBL] [Abstract][Full Text] [Related]
45. Clinical applications of spectral molecular imaging: potential and challenges.
Anderson NG; Butler AP
Contrast Media Mol Imaging; 2014; 9(1):3-12. PubMed ID: 24470290
[TBL] [Abstract][Full Text] [Related]
46. Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters.
Bao X; Wang MW; Luo JM; Wang SY; Zhang YP; Zhang YJ
Theranostics; 2016; 6(12):2084-2098. PubMed ID: 27698942
[No Abstract] [Full Text] [Related]
47. Synthesis, in vitro and in vivo evaluation of radiolabeled nanoparticles.
Shokeen M; Fettig NM; Rossin R
Q J Nucl Med Mol Imaging; 2008 Sep; 52(3):267-77. PubMed ID: 18475250
[TBL] [Abstract][Full Text] [Related]
48. Advancing Drug Discovery and Development Using Molecular Imaging (ADDMI): an Interest Group of the World Molecular Imaging Society and an Inaugural Session on Positron Emission Tomography (PET).
Patel S; Schmidt K; Hesterman J; Hoppin J
Mol Imaging Biol; 2017 Jun; 19(3):348-356. PubMed ID: 28417265
[TBL] [Abstract][Full Text] [Related]
49. Accelerating Regulatory Science Initiatives for the Development of Drugs for Alzheimer's Disease in Japan.
Moritoyo T
Clin Ther; 2015 Aug; 37(8):1622-6. PubMed ID: 26342202
[TBL] [Abstract][Full Text] [Related]
50. Trends in microdosing and other exploratory human pharmacokinetic studies for early drug development.
Oosterhuis B
Bioanalysis; 2010 Mar; 2(3):377-9. PubMed ID: 21083246
[No Abstract] [Full Text] [Related]
51. Molecular Imaging: a Novel Tool To Visualize Pathogenesis of Infections
Gordon O; Ruiz-Bedoya CA; Ordonez AA; Tucker EW; Jain SK
mBio; 2019 Oct; 10(5):. PubMed ID: 31662452
[TBL] [Abstract][Full Text] [Related]
52. Radiopharmaceutical chemistry for positron emission tomography.
Li Z; Conti PS
Adv Drug Deliv Rev; 2010 Aug; 62(11):1031-51. PubMed ID: 20854860
[TBL] [Abstract][Full Text] [Related]
53. [Development and evaluation of new drugs and medical devices in Japan--standpoint of regulatory agency].
Maruyama H; Kondo T
Brain Nerve; 2010 Mar; 62(3):263-8. PubMed ID: 20297731
[TBL] [Abstract][Full Text] [Related]
54. Medical nanotechnology: shortening clinical trials and regulatory pathways?
Ferrari M; Downing G
BioDrugs; 2005; 19(4):203-10. PubMed ID: 16128604
[TBL] [Abstract][Full Text] [Related]
55. Small-animal PET: a promising, non-invasive tool in pre-clinical research.
Schnöckel U; Hermann S; Stegger L; Law M; Kuhlmann M; Schober O; Schäfers K; Schäfers M
Eur J Pharm Biopharm; 2010 Jan; 74(1):50-4. PubMed ID: 19482080
[TBL] [Abstract][Full Text] [Related]
56. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
57. Providing Quality Therapeutics in Switzerland: Role of the Stakeholders and Recent Incentives for Further Improvements.
Besson M; Samer C; Rollason V; Dayer P; Desmeules J
Clin Ther; 2015 Jul; 37(7):1588-92. PubMed ID: 26049714
[TBL] [Abstract][Full Text] [Related]
58. Marmoset Serotonin 5-HT1A Receptor Mapping with a Biased Agonist PET Probe 18F-F13714: Comparison with an Antagonist Tracer 18F-MPPF in Awake and Anesthetized States.
Yokoyama C; Mawatari A; Kawasaki A; Takeda C; Onoe K; Doi H; Newman-Tancredi A; Zimmer L; Onoe H
Int J Neuropsychopharmacol; 2016 Dec; 19(12):. PubMed ID: 27608810
[TBL] [Abstract][Full Text] [Related]
59. The use of pharmacometrics to optimize biosimilar development.
Dodds M; Chow V; Markus R; Pérez-Ruixo JJ; Shen D; Gibbs M
J Pharm Sci; 2013 Nov; 102(11):3908-14. PubMed ID: 24027111
[TBL] [Abstract][Full Text] [Related]
60. PET/MRI: a new technology in the field of molecular imaging.
Afaq A; Syed R; Bomanji J
Br Med Bull; 2013; 108():159-71. PubMed ID: 24227824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
